{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:52:07Z","timestamp":1790776327946,"version":"4.1.0"},"reference-count":117,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T00:00:00Z","timestamp":1582761600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["5UO1 AG048310-04"],"award-info":[{"award-number":["5UO1 AG048310-04"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Disease"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.nbd.2020.104823","type":"journal-article","created":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T03:04:54Z","timestamp":1582859094000},"page":"104823","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"special_numbering":"C","title":["Characterization and preclinical evaluation of the cGMP grade DNA based vaccine, AV-1959D to enter the first-in-human clinical trials"],"prefix":"10.1016","volume":"139","author":[{"given":"Irina","family":"Petrushina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armine","family":"Hovakimyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indira S.","family":"Harahap-Carrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayk","family":"Davtyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatevik","family":"Antonyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gor","family":"Chailyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Kazarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxim","family":"Antonenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandine","family":"Jullienne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary M.","family":"Hamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0081-6950","authenticated-orcid":false,"given":"Andre","family":"Obenaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Zagorski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7770-7157","authenticated-orcid":false,"given":"Mathew","family":"Blurton-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Cribbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Lander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5436-0616","authenticated-orcid":false,"given":"Anahit","family":"Ghochikyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Agadjanyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nbd.2020.104823_bb0005","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s12026-008-8076-3","article-title":"DNA vaccines: developing new strategies to enhance immune responses","volume":"42","author":"Abdulhaqq","year":"2008","journal-title":"Immunol. Res."},{"key":"10.1016\/j.nbd.2020.104823_bb0010","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12883-017-0850-1","article-title":"Bapineuzumab for mild to moderate Alzheimer\u2019s disease: a meta-analysis of randomized controlled trials","volume":"17","author":"Abushouk","year":"2017","journal-title":"BMC Neurol."},{"key":"10.1016\/j.nbd.2020.104823_bb0015","first-page":"175","article-title":"DNA plasmid based vaccination against the oncogenic human T cell leukemia virus type 1","volume":"226","author":"Agadjanyan","year":"1998","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.nbd.2020.104823_bb0020","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.4049\/jimmunol.174.3.1580","article-title":"Prototype Alzheimer\u2019s disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide","volume":"174","author":"Agadjanyan","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.nbd.2020.104823_bb0025","article-title":"Active and passive A\u03b2-immunotherapy: positive and negative outcomes from pre-clinical and clinical trials and future directions","volume":"8","author":"Agadjanyan","year":"2009","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.nbd.2020.104823_bb0030","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.jalz.2015.06.1884","article-title":"A fresh perspective from immunologists and vaccine researchers: active vaccination strategies to prevent and reverse Alzheimer\u2019s disease","volume":"11","author":"Agadjanyan","year":"2015","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.nbd.2020.104823_bb0035","doi-asserted-by":"crossref","first-page":"242","DOI":"10.2174\/1567205012666150302154121","article-title":"Vanutide Cridificar and the QS-21 adjuvant in Japanese subjects with mild to moderate Alzheimer\u2019 s disease: results from two phase 2 studies","volume":"12","author":"Arai","year":"2015","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.nbd.2020.104823_bb0040","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1016\/S0264-410X(02)00269-4","article-title":"Electroporation improves the efficacy of DNA vaccines in large animals","volume":"20","author":"Babiuk","year":"2002","journal-title":"Vaccine."},{"key":"10.1016\/j.nbd.2020.104823_bb0045","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0264-410X(02)00574-1","article-title":"Induction of immune responses by DNA vaccines in large animals","volume":"21","author":"Babiuk","year":"2003","journal-title":"Vaccine."},{"issue":"1","key":"10.1016\/j.nbd.2020.104823_bb0050","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/14712598.2019.1554646","article-title":"A vaccine against Alzheimer\u2019s disease: anything left but faith?","volume":"19","author":"Bachmann","year":"2019","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.nbd.2020.104823_bb0055","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3004414","article-title":"Immunotherapy against HPV16\/18 generates potent TH1 and cytotoxic cellular immune responses","volume":"4","author":"Bagarazzi","year":"2012","journal-title":"Sci. Transl. Med."},{"issue":"6","key":"10.1016\/j.nbd.2020.104823_bb0060","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1159\/000455837","article-title":"Susceptibility-weighted imaging identifies iron-oxide-labeled human neural stem cells: automated computational detection","volume":"38","author":"Baghchechi","year":"2016","journal-title":"Dev. Neurosci."},{"key":"10.1016\/j.nbd.2020.104823_bb0065","first-page":"109","article-title":"Recent advances towards the clinical application of DNA vaccines","volume":"71","author":"Bins","year":"2013","journal-title":"Neth. J. Med."},{"key":"10.1016\/j.nbd.2020.104823_bb0070","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1093\/brain\/awn261","article-title":"Consequence of Abeta immunization on the vasculature of human Alzheimer\u2019s disease brain","volume":"131","author":"Boche","year":"2008","journal-title":"Brain."},{"key":"10.1016\/j.nbd.2020.104823_bb0075","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/mt.2009.5","article-title":"Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developments","volume":"17","author":"Bodles-Brakhop","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.nbd.2020.104823_bb0080","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.jalz.2011.05.2353","article-title":"Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab","volume":"7","author":"Carlson","year":"2011","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.nbd.2020.104823_bb0085","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1007\/s00262-012-1270-0","article-title":"DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time","volume":"61","author":"Chudley","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.nbd.2020.104823_bb0090","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nn1372","article-title":"Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function","volume":"8","author":"Cleary","year":"2005","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.nbd.2020.104823_bb0095","doi-asserted-by":"crossref","first-page":"S567","DOI":"10.3233\/JAD-179941","article-title":"The amyloid-beta oligomer hypothesis: beginning of the third decade","volume":"64","author":"Cline","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.nbd.2020.104823_bb0100","doi-asserted-by":"crossref","first-page":"20296","DOI":"10.1074\/jbc.M312946200","article-title":"Early-onset and robust cerebral microvascular accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch\/Iowa mutant form of amyloid beta-protein precursor","volume":"279","author":"Davis","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2020.104823_bb0105","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.neurobiolaging.2005.05.031","article-title":"Deficient cerebral clearance of vasculotropic mutant Dutch\/Iowa double a beta in human a betaPP transgenic mice","volume":"27","author":"Davis","year":"2006","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.nbd.2020.104823_bb0110","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/gt.2009.140","article-title":"DNA prime-protein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wild-type mice","volume":"17","author":"Davtyan","year":"2010","journal-title":"Gene Ther."},{"key":"10.1016\/j.nbd.2020.104823_bb0115","doi-asserted-by":"crossref","first-page":"4923","DOI":"10.1523\/JNEUROSCI.4672-12.2013","article-title":"Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer\u2019s disease: prelude to a clinical trial","volume":"33","author":"Davtyan","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2020.104823_bb0120","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jalz.2013.12.003","article-title":"The MultiTEP platform-based Alzheimer\u2019s disease epitope vaccine activates a broad repertoire of T helper cells in nonhuman primates","volume":"10","author":"Davtyan","year":"2014","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.nbd.2020.104823_bb0125","doi-asserted-by":"crossref","first-page":"190","DOI":"10.2174\/1566523214666140522121427","article-title":"BTX AgilePulse(TM) system is an effective electroporation device for intramuscular and intradermal delivery of DNA vaccine","volume":"14","author":"Davtyan","year":"2014","journal-title":"Curr. Gene. Ther."},{"issue":"Suppl. 1","key":"10.1016\/j.nbd.2020.104823_bb0130","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1471-4159.2011.07458.x","article-title":"Clinical trials in Alzheimer\u2019s disease\u2019: immunotherapy approaches","volume":"120","author":"Delrieu","year":"2012","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2020.104823_bb0135","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1742-4933-5-11","article-title":"Immunity, ageing and cancer","volume":"5","author":"Derhovanessian","year":"2008","journal-title":"Immun. Ageing"},{"key":"10.1016\/j.nbd.2020.104823_bb0140","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.4161\/hv.24702","article-title":"Tolerability of intramuscular and intradermal delivery by CELLECTRA((R)) adaptive constant current electroporation device in healthy volunteers","volume":"9","author":"Diehl","year":"2013","journal-title":"Hum. Vaccin Immunother."},{"key":"10.1016\/j.nbd.2020.104823_bb0145","doi-asserted-by":"crossref","first-page":"633","DOI":"10.4049\/jimmunol.175.2.633","article-title":"DNA vaccines: progress and challenges","volume":"175","author":"Donnelly","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.nbd.2020.104823_bb0150","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/mt.2011.235","article-title":"Safety and tolerability of the easy vax clinical epidermal electroporation system in healthy adults","volume":"20","author":"El-Kamary","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.nbd.2020.104823_bb0155","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1016\/j.vaccine.2013.06.063","article-title":"DNA vaccine coding for the rhesus prostate specific antigen delivered by intradermal electroporation in patients with relapsed prostate cancer","volume":"31","author":"Eriksson","year":"2013","journal-title":"Vaccine."},{"key":"10.1016\/j.nbd.2020.104823_bb0160","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jalz.2013.04.505","article-title":"Epitope-based DNA vaccine for Alzheimer\u2019s disease: translational study in macaques","volume":"10","author":"Evans","year":"2014","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.nbd.2020.104823_bb0165","series-title":"Points to Consider on Plasmid DNA Vaccines for Preventive Infectious Diseases Indications","author":"FDA","year":"1996"},{"key":"10.1016\/j.nbd.2020.104823_bb0170","series-title":"Guidance for Industry: Considerations for Plasmid DNA Vaccines for Infectious Disease Indications","author":"FDA","year":"2007"},{"key":"10.1016\/j.nbd.2020.104823_bb0175","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/cid\/cir334","article-title":"Clinical applications of DNA vaccines: current progress","volume":"53","author":"Ferraro","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.nbd.2020.104823_bb0180","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1750-3639.2004.tb00493.x","article-title":"Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease","volume":"14","author":"Ferrer","year":"2004","journal-title":"Brain Pathol."},{"key":"10.1016\/j.nbd.2020.104823_bb0185","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1212\/01.WNL.0000159743.08996.99","article-title":"Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease","volume":"64","author":"Fox","year":"2005","journal-title":"Neurology."},{"key":"10.1016\/j.nbd.2020.104823_bb0190","doi-asserted-by":"crossref","first-page":"128","DOI":"10.2174\/187152709787847298","article-title":"Rationale for peptide and DNA based epitope vaccines for Alzheimer\u2019s disease immunotherapy","volume":"8","author":"Ghochikyan","year":"2009","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.nbd.2020.104823_bb0195","article-title":"CAD-106, a beta-amyloid-based immunotherapeutic for Alzheimer\u2019s disease","author":"Ghochikyan","year":"2012","journal-title":"Thompson Reuter"},{"key":"10.1016\/j.nbd.2020.104823_bb0200","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1002\/eji.200324000","article-title":"Generation and chracterization of the humoral immune response to DNA immunization with a chimeric b-amyloid-interleukin-4 minigene","volume":"33","author":"Ghochikyan","year":"2003","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.nbd.2020.104823_bb0205","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1016\/j.vaccine.2005.11.039","article-title":"Prototype Alzheimer\u2019s disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with alum to Quil a adjuvant switch","volume":"24","author":"Ghochikyan","year":"2006","journal-title":"Vaccine."},{"key":"10.1016\/j.nbd.2020.104823_bb0210","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.4161\/hv.23875","article-title":"Refinement of a DNA based Alzheimer's disease epitope vaccine in rabbits","volume":"9","author":"Ghochikyan","year":"2013","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.nbd.2020.104823_bb0215","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1038\/jcbfm.2012.121","article-title":"Automated core-penumbra quantification in neonatal ischemic brain injury","volume":"32","author":"Ghosh","year":"2012","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.nbd.2020.104823_bb0220","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","article-title":"Clinical effects of Abeta immunization (AN1792) in patients with AD in AN interrupted trial","volume":"64","author":"Gilman","year":"2005","journal-title":"Neurology."},{"key":"10.1016\/j.nbd.2020.104823_bb0225","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.pharep.2015.07.006","article-title":"Therapeutic strategies for Alzheimer\u2019s disease in clinical trials","volume":"68","author":"Godyn","year":"2016","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.nbd.2020.104823_bb0230","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2174\/156720506779025189","article-title":"Filling the gaps in the abeta cascade hypothesis of Alzheimer\u2019s disease","volume":"3","author":"Golde","year":"2006","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.nbd.2020.104823_bb0235","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrm2101","article-title":"Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer\u2019s amyloid beta-peptide","volume":"8","author":"Haass","year":"2007","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.nbd.2020.104823_bb0240","series-title":"EMERGE and ENGAGE Topline Results: Two Phase 3 Studies to Evaluate Aducanumab in Patients With Early Alzheimer\u2019s Disease","author":"Haeberlein","year":"2019"},{"key":"10.1016\/j.nbd.2020.104823_bb0245","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2174\/156720506775697098","article-title":"Has the amyloid cascade hypothesis for Alzheimer\u2019s disease been proved?","volume":"3","author":"Hardy","year":"2006","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.nbd.2020.104823_bb0250","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer\u2019s disease: the amyloid cascade hypothesis","volume":"256","author":"Hardy","year":"1992","journal-title":"Science."},{"key":"10.1016\/j.nbd.2020.104823_bb0255","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s11481-007-9069-z","article-title":"Microglial activation is required for Abeta clearance after intracranial injection of lipopolysaccharide in APP transgenic mice","volume":"2","author":"Herber","year":"2007","journal-title":"J. NeuroImmune Pharmacol."},{"key":"10.1016\/j.nbd.2020.104823_bb0260","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19113605","article-title":"DNA vaccines-how far from clinical use?","volume":"19","author":"Hobernik","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.nbd.2020.104823_bb0265","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(08)61075-2","article-title":"Long-term effects of Abeta42 immunization in Alzheimer\u2019s disease: follow-up of a randomised, placebo-controlled phase I trial","volume":"372","author":"Holmes","year":"2008","journal-title":"Lancet."},{"key":"10.1016\/j.nbd.2020.104823_bb0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0169-328X(98)00040-0","article-title":"Microglia-specific localisation of a novel calcium binding protein, Iba1","volume":"57","author":"Ito","year":"1998","journal-title":"Brain Res. Mol. Brain Res."},{"key":"10.1016\/j.nbd.2020.104823_bb0275","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1517\/14712598.2010.493872","article-title":"Bapineuzumab","volume":"10","author":"Kerchner","year":"2010","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.nbd.2020.104823_bb0280","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/S0264-410X(98)00177-7","article-title":"Engineering DNA vaccines via co-delivery of co-stimulatory molecule genes","volume":"16","author":"Kim","year":"1998","journal-title":"Vaccine."},{"key":"10.1016\/j.nbd.2020.104823_bb0285","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.neurobiolaging.2004.02.010","article-title":"Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer\u2019s disease","volume":"25","author":"Klein","year":"2004","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.nbd.2020.104823_bb0290","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3389\/fnagi.2014.00032","article-title":"Imaging of cerebrovascular pathology in animal models of Alzheimer\u2019s disease","volume":"6","author":"Klohs","year":"2014","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.nbd.2020.104823_bb0295","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1161\/HYPERTENSIONAHA.115.05524","article-title":"Chronic hypertension leads to neurodegeneration in the TgSwDI mouse model of Alzheimer\u2019s disease","volume":"66","author":"Kruyer","year":"2015","journal-title":"Hypertension."},{"key":"10.1016\/j.nbd.2020.104823_bb0300","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1523\/JNEUROSCI.3501-06.2007","article-title":"Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer\u2019s disease","volume":"27","author":"Lacor","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2020.104823_bb0305","doi-asserted-by":"crossref","first-page":"6448","DOI":"10.1073\/pnas.95.11.6448","article-title":"Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins","volume":"95","author":"Lambert","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2020.104823_bb0310","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrneurol.2009.219","article-title":"Can Alzheimer disease be prevented by amyloid-beta immunotherapy?","volume":"6","author":"Lemere","year":"2010","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.nbd.2020.104823_bb0315","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jbiotec.2012.08.012","article-title":"The future of human DNA vaccines","volume":"162","author":"Li","year":"2012","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.nbd.2020.104823_bb0320","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1600-065X.2010.00980.x","article-title":"DNA vaccines: an historical perspective and view to the future","volume":"239","author":"Liu","year":"2011","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.nbd.2020.104823_bb0325","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0065-2660(05)55002-8","article-title":"Human clinical trials of plasmid DNA vaccines","volume":"55","author":"Liu","year":"2005","journal-title":"Adv. Genet."},{"key":"10.1016\/j.nbd.2020.104823_bb0330","first-page":"628070","article-title":"Targeting Beta amyloid: a clinical review of immunotherapeutic approaches in Alzheimer\u2019s disease","volume":"2012","author":"Lobello","year":"2012","journal-title":"Int. J. Alzheimers Dis."},{"key":"10.1016\/j.nbd.2020.104823_bb0335","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s13046-019-1154-7","article-title":"Cancer DNA vaccines: current preclinical and clinical developments and future perspectives","volume":"38","author":"Lopes","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.nbd.2020.104823_bb0340","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1517\/14712598.7.11.1647","article-title":"Electroporation-based DNA immunisation: translation to the clinic","volume":"7","author":"Luxembourg","year":"2007","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.nbd.2020.104823_bb0345","doi-asserted-by":"crossref","first-page":"156","DOI":"10.2174\/187152710791012071","article-title":"Microglia and inflammation in Alzheimer\u2019s disease","volume":"9","author":"Mandrekar-Colucci","year":"2010","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.nbd.2020.104823_bb0350","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/jnc.13608","article-title":"A retrospective analysis of the Alzheimer\u2019s disease vaccine progress - the critical need for new development strategies","volume":"137","author":"Marciani","year":"2016","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2020.104823_bb0355","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ymthe.2006.06.010","article-title":"Complete regression of established subcutaneous B16 murine melanoma tumors after delivery of an HIV-1 Vpr-expressing plasmid by in vivo electroporation","volume":"14","author":"McCray","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.nbd.2020.104823_bb0360","doi-asserted-by":"crossref","first-page":"6271","DOI":"10.1523\/JNEUROSCI.1306-05.2005","article-title":"Reducing cerebral microvascular amyloid-beta protein deposition diminishes regional neuroinflammation in vasculotropic mutant amyloid precursor protein transgenic mice","volume":"25","author":"Miao","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2020.104823_bb0365","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0002-9440(10)62993-8","article-title":"Cerebral microvascular amyloid beta protein deposition induces vascular degeneration and neuroinflammation in transgenic mice expressing human vasculotropic mutant amyloid beta precursor protein","volume":"167","author":"Miao","year":"2005","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.nbd.2020.104823_bb0370","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1371\/journal.pone.0002124","article-title":"Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine- a novel immunotherapeutic strategy","volume":"3","author":"Movsesyan","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.nbd.2020.104823_bb0375","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jneuroim.2008.08.016","article-title":"DNA epitope vaccine containing complement component C3d enhances anti-amyloid-beta antibody production and polarizes the immune response towards a Th2 phenotype","volume":"205","author":"Movsesyan","year":"2008","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.nbd.2020.104823_bb0380","series-title":"Aducanumab (BIIB037) reduced brain amyloid plaque levels and slowed cognitive decline in patients with prodromal or mild Alzheimer's disease in Phase 1b study. Biogen IDEC presents positive interim results from Phase 1b study at 2015 AD\/PD conference","author":"Neurimmune","year":"2015"},{"key":"10.1016\/j.nbd.2020.104823_bb0385","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nm840","article-title":"Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report","volume":"9","author":"Nicoll","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.nbd.2020.104823_bb0390","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1097\/01.jnen.0000240466.10758.ce","article-title":"Abeta species removal after abeta42 immunization","volume":"65","author":"Nicoll","year":"2006","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.nbd.2020.104823_bb0395","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131748","article-title":"HIV-DNA given with or without intradermal electroporation is safe and highly immunogenic in healthy Swedish HIV-1 DNA\/MVA Vaccinees: a phase I randomized trial","volume":"10","author":"Nilsson","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.nbd.2020.104823_bb0400","series-title":"Brain Edema: From Molecular Mechanisms to Clinical Practice","article-title":"Neuroimaging of brain Edema","author":"Obenaus","year":"2017"},{"key":"10.1016\/j.nbd.2020.104823_bb0405","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/s41598-017-00161-4","article-title":"Traumatic brain injury results in acute rarefication of the vascular network","volume":"7","author":"Obenaus","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.nbd.2020.104823_bb0410","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","article-title":"Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization","volume":"61","author":"Orgogozo","year":"2003","journal-title":"Neurology."},{"key":"10.1016\/j.nbd.2020.104823_bb0415","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1001\/archneurol.2011.1538","article-title":"Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab","volume":"69","author":"Ostrowitzki","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.nbd.2020.104823_bb0420","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","article-title":"A phase III randomized trial of gantenerumab in prodromal Alzheimer\u2019s disease","volume":"9","author":"Ostrowitzki","year":"2017","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.nbd.2020.104823_bb0425","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1586\/1744666X.2014.883921","article-title":"Amyloid-based immunotherapy for Alzheimer\u2019s disease in the time of prevention trials: the way forward","volume":"10","author":"Panza","year":"2014","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"10.1016\/j.nbd.2020.104823_bb0430","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/14712598.2018.1389885","article-title":"The potential of solanezumab and gantenerumab to prevent Alzheimer\u2019s disease in people with inherited mutations that cause its early onset","volume":"18","author":"Panza","year":"2018","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.nbd.2020.104823_bb0435","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2217\/imt-2018-0119","article-title":"Are antibodies directed against amyloid-beta (Abeta) oligomers the last call for the Abeta hypothesis of Alzheimer's disease?","volume":"11","author":"Panza","year":"2019","journal-title":"Immunotherapy."},{"key":"10.1016\/j.nbd.2020.104823_bb0440","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/j.ajpath.2013.01.021","article-title":"The bradykinin B1 receptor regulates Abeta deposition and neuroinflammation in Tg-SwDI mice","volume":"182","author":"Passos","year":"2013","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.nbd.2020.104823_bb0445","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1742-2094-2-9","article-title":"Inflammatory cytokine levels correlate with amyloid load in transgenic mouse models of Alzheimer\u2019s disease","volume":"2","author":"Patel","year":"2005","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.nbd.2020.104823_bb0450","doi-asserted-by":"crossref","first-page":"12721","DOI":"10.1523\/JNEUROSCI.3201-07.2007","article-title":"Alzheimer\u2019s disease peptide epitope vaccine reduces insoluble but not soluble\/oligomeric A{beta} species in amyloid precursor protein transgenic mice","volume":"27","author":"Petrushina","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2020.104823_bb0455","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ymthe.2016.10.002","article-title":"Comparison of efficacy of preventive and therapeutic vaccines targeting the N terminus of beta-amyloid in an animal model of Alzheimer\u2019s disease","volume":"25","author":"Petrushina","year":"2017","journal-title":"Mol. Ther."},{"issue":"8","key":"10.1016\/j.nbd.2020.104823_bb0460","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1002\/glia.23336","article-title":"Gliovascular changes precede white matter damage and long-term disorders in juvenile mild closed head injury","volume":"66","author":"Rodriguez-Grande","year":"2018","journal-title":"Glia."},{"key":"10.1016\/j.nbd.2020.104823_bb0465","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ymthe.2005.08.005","article-title":"Enhancement of cellular immune response to a prostate cancer DNA vaccine by intradermal electroporation","volume":"13","author":"Roos","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.nbd.2020.104823_bb0470","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3233\/JAD-2009-1118","article-title":"Anti-amyloid-beta immunotherapy in Alzheimer\u2019s disease: ACC-001 clinical trials are ongoing","volume":"17","author":"Ryan","year":"2009","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.nbd.2020.104823_bb0475","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13195-018-0424-5","article-title":"Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer\u2019s disease (BLAZE)","volume":"10","author":"Salloway","year":"2018","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.nbd.2020.104823_bb0480","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.coi.2011.03.008","article-title":"Electroporation delivery of DNA vaccines: prospects for success","volume":"23","author":"Sardesai","year":"2011","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.nbd.2020.104823_bb0485","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4161\/hv.2.2.2620","article-title":"Preclinical and clinical safety studies on DNA vaccines","volume":"2","author":"Schalk","year":"2006","journal-title":"Hum. Vaccin."},{"key":"10.1016\/j.nbd.2020.104823_bb0490","doi-asserted-by":"crossref","first-page":"948","DOI":"10.4161\/hv.6.11.13217","article-title":"AFFITOME(R) technology in neurodegenerative diseases: the doubling advantage","volume":"6","author":"Schneeberger","year":"2010","journal-title":"Hum. Vaccin."},{"key":"10.1016\/j.nbd.2020.104823_bb0495","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0896-6273(91)90052-2","article-title":"The molecular pathology of Alzheimer\u2019s disease","volume":"6","author":"Selkoe","year":"1991","journal-title":"Neuron."},{"key":"10.1016\/j.nbd.2020.104823_bb0500","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/00005072-199409000-00003","article-title":"Alzheimer\u2019s disease: a central role for amyloid","volume":"53","author":"Selkoe","year":"1994","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.nbd.2020.104823_bb0505","doi-asserted-by":"crossref","first-page":"5921","DOI":"10.1021\/acs.biochem.8b00985","article-title":"Light at the end of the amyloid TunnelPublished as part of the biochemistry series \u201cbiochemistry to bedside\u201d","volume":"57","author":"Selkoe","year":"2018","journal-title":"Biochemistry."},{"key":"10.1016\/j.nbd.2020.104823_bb0510","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41582-019-0205-1","article-title":"Alzheimer disease and aducanumab: adjusting our approach","volume":"15","author":"Selkoe","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.nbd.2020.104823_bb0515","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces Abeta plaques in Alzheimer\u2019s disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature."},{"key":"10.1016\/j.nbd.2020.104823_bb0520","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1523\/JNEUROSCI.4970-06.2007","article-title":"Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway","volume":"27","author":"Shankar","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2020.104823_bb0525","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/nm1782","article-title":"Amyloid-beta protein dimers isolated directly from Alzheimer\u2019s brains impair synaptic plasticity and memory","volume":"14","author":"Shankar","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.nbd.2020.104823_bb0530","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a024075","article-title":"Binding sites for amyloid-beta oligomers and synaptic toxicity","volume":"7","author":"Smith","year":"2017","journal-title":"Cold Spring Harb Perspect Med."},{"key":"10.1016\/j.nbd.2020.104823_bb0535","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3389\/fnagi.2014.00114","article-title":"Immunotherapy for Alzheimer\u2019s disease: past, present and future","volume":"6","author":"Spencer","year":"2014","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.nbd.2020.104823_bb0540","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/sj.cgt.7700973","article-title":"Regression of subcutaneous B16 melanoma tumors after intratumoral delivery of an IL-15-expressing plasmid followed by in vivo electroporation","volume":"13","author":"Ugen","year":"2006","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.nbd.2020.104823_bb0545","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1586\/erv.10.42","article-title":"Electroporation for DNA immunization: clinical application","volume":"9","author":"van Drunen Littel-Van den Hurk","year":"2010","journal-title":"Expert Rev. Vaccines."},{"key":"10.1016\/j.nbd.2020.104823_bb0550","doi-asserted-by":"crossref","first-page":"13376","DOI":"10.1523\/JNEUROSCI.2788-07.2007","article-title":"Experimental investigation of antibody-mediated clearance mechanisms of amyloid-beta in CNS of Tg-SwDI transgenic mice","volume":"27","author":"Vasilevko","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2020.104823_bb0555","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0206838","article-title":"Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140\/GLA vaccines in a phase II randomized factorial trial design","volume":"13","author":"Viegas","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.nbd.2020.104823_bb0560","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1016\/j.vaccine.2007.01.031","article-title":"Site-specific UBITh amyloid-beta vaccine for immunotherapy of Alzheimer\u2019s disease","volume":"25","author":"Wang","year":"2007","journal-title":"Vaccine."},{"key":"10.1016\/j.nbd.2020.104823_bb0565","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.trci.2017.03.005","article-title":"UB-311, a novel UBITh((R)) amyloid beta peptide vaccine for mild Alzheimer\u2019s disease","volume":"3","author":"Wang","year":"2017","journal-title":"Alzheimers Dement (N Y)."},{"key":"10.1016\/j.nbd.2020.104823_bb0570","first-page":"113","article-title":"Results of the first-in-man study with the active Abeta immunotherapy CAD106 in Alzheimer\u2019s patients","volume":"5","author":"Winblad","year":"2009","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/j.nbd.2020.104823_bb0575","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1474-4422(12)70140-0","article-title":"Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study","volume":"11","author":"Winblad","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.nbd.2020.104823_bb0580","doi-asserted-by":"crossref","first-page":"160","DOI":"10.2174\/187152709787847289","article-title":"AD vaccines: conclusions and future directions","volume":"8","author":"Wisniewski","year":"2009","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.nbd.2020.104823_bb0585","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3233\/JAD-2011-101401","article-title":"Blocking the apolipoprotein E\/amyloid-beta interaction reduces fibrillar vascular amyloid deposition and cerebral microhemorrhages in TgSwDI mice","volume":"24","author":"Yang","year":"2011","journal-title":"J. Alzheimers Dis."}],"container-title":["Neurobiology of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096999612030098X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096999612030098X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T05:17:14Z","timestamp":1760851034000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096999612030098X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":117,"alternative-id":["S096999612030098X"],"URL":"https:\/\/doi.org\/10.1016\/j.nbd.2020.104823","relation":{},"ISSN":["0969-9961"],"issn-type":[{"value":"0969-9961","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization and preclinical evaluation of the cGMP grade DNA based vaccine, AV-1959D to enter the first-in-human clinical trials","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nbd.2020.104823","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"104823"}}